Regulatory Filings • Jun 8, 2021
Regulatory Filings
Open in ViewerOpens in native device viewer
ADDING THE POPULAR PAY PER PROCEDURE BUSINESS MODEL TO THE MiraQ PLATFORM
(Oslo, 8th of June 2021) Medistim ASA (OSE: MEDI) is a niche market leader within ultrasound technology with headquarters in Oslo, Norway. Medistim develops and commercializes medical equipment for use within cardiac, vascular and transplant surgery. Today, Medistim announces the launch of the Pay Per Procedure (PPP) functionality to our latest MiraQTM platform in the US market.
Medistim utilizes several business models to effectively reach different segments of the US market. In addition to traditional capital investments and purchase of consumables, hospitals can choose to enter leasing agreements or Pay Per Procedure (PPP). The PPP functionality has proven to be a popular option with our previous generation of medical device (VeriQTM and VeriQCTM and will now also be available to our MiraQ customers.
“Some of our largest customers in the USA are greatly appreciating the PPP model with their current VeriQTM platform and Medistim wants to make their transition to the latest platform MiraQTM as smooth as possible,” says Medistim President and CEO, Kari E. Krogstad. “The US market is key to Medistim’s success, making up about 1/3 of the global potential market, and it is our priority to respond to our customers’ preferences.”
About Medistim:
Medistim was established in 1984 and has a track record of profitable growth over the past 20 years. The company is a pioneer within its segment and continues to invest in new product development. Medistim has wholly owned subsidiaries with sales organizations in the USA, Germany, UK, Spain, Denmark, and Norway, in addition to the about 50 distributors in Europe, Asia, Middle East, Africa, Canada and South America. For more information, visit the Medistim home page: www.medistim.com
For more information, contact:
President and CEO, Kari E. Krogstad, Medistim ASA
Tel: + 47 918 38 110
Email: [email protected]
CFO, Thomas Jakobsen, Medistim ASA
Tel: + 47 906 59 940
Email: [email protected]
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.